A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Pazopanib (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jan 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Jun 2012 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.